These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

778 related articles for article (PubMed ID: 29101163)

  • 1. CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation.
    Deng J; Wang ES; Jenkins RW; Li S; Dries R; Yates K; Chhabra S; Huang W; Liu H; Aref AR; Ivanova E; Paweletz CP; Bowden M; Zhou CW; Herter-Sprie GS; Sorrentino JA; Bisi JE; Lizotte PH; Merlino AA; Quinn MM; Bufe LE; Yang A; Zhang Y; Zhang H; Gao P; Chen T; Cavanaugh ME; Rode AJ; Haines E; Roberts PJ; Strum JC; Richards WG; Lorch JH; Parangi S; Gunda V; Boland GM; Bueno R; Palakurthi S; Freeman GJ; Ritz J; Haining WN; Sharpless NE; Arthanari H; Shapiro GI; Barbie DA; Gray NS; Wong KK
    Cancer Discov; 2018 Feb; 8(2):216-233. PubMed ID: 29101163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
    Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
    Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDK4/6 Inhibition Promotes Antitumor Immunity through the Induction of T-cell Memory.
    Lelliott EJ; Kong IY; Zethoven M; Ramsbottom KM; Martelotto LG; Meyran D; Zhu JJ; Costacurta M; Kirby L; Sandow JJ; Lim L; Dominguez PM; Todorovski I; Haynes NM; Beavis PA; Neeson PJ; Hawkins ED; McArthur GA; Parish IA; Johnstone RW; Oliaro J; Sheppard KE; Kearney CJ; Vervoort SJ
    Cancer Discov; 2021 Oct; 11(10):2582-2601. PubMed ID: 33990344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bifunctional iRGD-anti-CD3 enhances antitumor potency of T cells by facilitating tumor infiltration and T-cell activation.
    Zhou S; Meng F; Du S; Qian H; Ding N; Sha H; Zhu M; Yu X; Wang L; Liu B; Wei J
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance.
    Zhang J; Bu X; Wang H; Zhu Y; Geng Y; Nihira NT; Tan Y; Ci Y; Wu F; Dai X; Guo J; Huang YH; Fan C; Ren S; Sun Y; Freeman GJ; Sicinski P; Wei W
    Nature; 2018 Jan; 553(7686):91-95. PubMed ID: 29160310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arrested Developments: CDK4/6 Inhibitor Resistance and Alterations in the Tumor Immune Microenvironment.
    Teh JLF; Aplin AE
    Clin Cancer Res; 2019 Feb; 25(3):921-927. PubMed ID: 30287548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-cell profiling guided combinatorial immunotherapy for fast-evolving CDK4/6 inhibitor-resistant HER2-positive breast cancer.
    Wang Q; Guldner IH; Golomb SM; Sun L; Harris JA; Lu X; Zhang S
    Nat Commun; 2019 Aug; 10(1):3817. PubMed ID: 31444334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autocrine Complement Inhibits IL10-Dependent T-cell-Mediated Antitumor Immunity to Promote Tumor Progression.
    Wang Y; Sun SN; Liu Q; Yu YY; Guo J; Wang K; Xing BC; Zheng QF; Campa MJ; Patz EF; Li SY; He YW
    Cancer Discov; 2016 Sep; 6(9):1022-35. PubMed ID: 27297552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.
    Sen T; Rodriguez BL; Chen L; Corte CMD; Morikawa N; Fujimoto J; Cristea S; Nguyen T; Diao L; Li L; Fan Y; Yang Y; Wang J; Glisson BS; Wistuba II; Sage J; Heymach JV; Gibbons DL; Byers LA
    Cancer Discov; 2019 May; 9(5):646-661. PubMed ID: 30777870
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Teh JLF; Cheng PF; Purwin TJ; Nikbakht N; Patel P; Chervoneva I; Ertel A; Fortina PM; Kleiber I; HooKim K; Davies MA; Kwong LN; Levesque MP; Dummer R; Aplin AE
    Cancer Discov; 2018 May; 8(5):568-581. PubMed ID: 29496664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy.
    Lai AY; Sorrentino JA; Dragnev KH; Weiss JM; Owonikoko TK; Rytlewski JA; Hood J; Yang Z; Malik RK; Strum JC; Roberts PJ
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33004541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
    Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
    Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic modulation by CDK4/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors.
    Uzhachenko RV; Bharti V; Ouyang Z; Blevins A; Mont S; Saleh N; Lawrence HA; Shen C; Chen SC; Ayers GD; DeNardo DG; Arteaga C; Richmond A; Vilgelm AE
    Cell Rep; 2021 Apr; 35(1):108944. PubMed ID: 33826903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
    Bisi JE; Sorrentino JA; Jordan JL; Darr DD; Roberts PJ; Tavares FX; Strum JC
    Oncotarget; 2017 Jun; 8(26):42343-42358. PubMed ID: 28418845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CDK4/6 Therapeutic Intervention and Viable Alternative to Taxanes in CRPC.
    Stice JP; Wardell SE; Norris JD; Yllanes AP; Alley HM; Haney VO; White HS; Safi R; Winter PS; Cocce KJ; Kishton RJ; Lawrence SA; Strum JC; McDonnell DP
    Mol Cancer Res; 2017 Jun; 15(6):660-669. PubMed ID: 28209757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDK4/6 inhibition triggers anti-tumour immunity.
    Goel S; DeCristo MJ; Watt AC; BrinJones H; Sceneay J; Li BB; Khan N; Ubellacker JM; Xie S; Metzger-Filho O; Hoog J; Ellis MJ; Ma CX; Ramm S; Krop IE; Winer EP; Roberts TM; Kim HJ; McAllister SS; Zhao JJ
    Nature; 2017 Aug; 548(7668):471-475. PubMed ID: 28813415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy.
    Roberts PJ; Bisi JE; Strum JC; Combest AJ; Darr DB; Usary JE; Zamboni WC; Wong KK; Perou CM; Sharpless NE
    J Natl Cancer Inst; 2012 Mar; 104(6):476-87. PubMed ID: 22302033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SPH3643: A novel cyclin-dependent kinase 4/6 inhibitor with good anticancer efficacy and strong blood-brain barrier permeability.
    Liao X; Hong Y; Mao Y; Chen N; Wang Q; Wang Z; Zhang L; Wang L; Shi C; Shi W; Ge H; Li A; Li X; Xia G; Liu Y
    Cancer Sci; 2020 May; 111(5):1761-1773. PubMed ID: 32103527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual pH-sensitive nanodrug blocks PD-1 immune checkpoint and uses T cells to deliver NF-κB inhibitor for antitumor immunotherapy.
    Xiao Z; Su Z; Han S; Huang J; Lin L; Shuai X
    Sci Adv; 2020 Feb; 6(6):eaay7785. PubMed ID: 32076650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cisplatin Augments Antitumor T-Cell Responses Leading to a Potent Therapeutic Effect in Combination With PD-L1 Blockade.
    Wakita D; Iwai T; Harada S; Suzuki M; Yamamoto K; Sugimoto M
    Anticancer Res; 2019 Apr; 39(4):1749-1760. PubMed ID: 30952714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.